June 26, 2024 CGM – Q&A document
26/06/2024 – Q&A document of the June 26, 2024 Combined General Meeting
26/06/2024 – Q&A document of the June 26, 2024 Combined General Meeting
31/05/2024 – AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS
30/05/2024 – Presentation of the AB Science webcast held on May 30, 2024
29/05/2024 – AB Science today announces that the CHMP adopted a trending toward a negative opinion on the application for conditional marketing authorisation of masitinib in ALS
17/05/2024 – AB Science communicates a corrective statement on the consolidated accounts as of December 31, 2023
15/05/2024 – AB Science reports its revenues for the year 2023 and provides an update on its activities
13/05/2024 – AB Science today announced that the European patent office has issued a Grant Decision for a patent relating to methods of treating severe mastocytosis with its lead compound masitinib
07/05/2024 – AB Science today announced the publication of an article in Muscle & Nerve, a peer-reviewed medical journal covering neuromuscular medicine
02/05/2024 – AB Science announced today that the Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science
30/04/2024 – The Company will publish its annual financial report no later than May 15, 2024